title: Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms.
abstract: In the present study we compared outcomes of patients with myeloid neoplasms undergoing allogeneic hematopoietic stem cell transplantation after fludarabine-based regimens with melphalan (FM140) or 3-day busulfan (FB3). The FM140 and FB3 combinations were administered to 21 and 27 patients, respectively. Efforts for early reduction (from day +30 to 60) and discontinuation (until day +100 to 130) of prophylactic immunosuppression were a component of the post-transplant approach. Following FB3 patients suffered from more severe stomatitis (P = 0.013). In contrast, other manifestations of regimen-related toxicity were more frequent in the FM140 group (P = 0.048). There were no statistically significant differences in the development of graft-versus-host disease, non-relapse mortality, post-transplant remission rate, or relapse incidence. Two-year disease-free survival rates were comparable in the two cohorts (66 vs. 55 %; P = 0.751), and so were the overall survival rates (64 vs. 62 %; P = 0.715). The outcomes of allografted patients with myeloid neoplasms were comparable after the FM140 and FB3 regimens. Relatively high therapeutic response in both groups may have been influenced by early reduction and discontinuation of prophylactic immunosuppression followed by effective immunological control of the malignant clone.
authors.affiliation: Department of Hemato-Oncology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic, raida@fnol.cz.
authors.forename: Ludek
authors.initials: L
authors.lastname: Raida
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Rusinakova
authors.forename: Edgar
authors.initials: E
authors.lastname: Faber
authors.forename: Romana
authors.initials: R
authors.lastname: Szotkowska
authors.forename: Peter
authors.initials: P
authors.lastname: Rohon
authors.forename: Ivana
authors.initials: I
authors.lastname: Skoumalova
authors.forename: Martina
authors.initials: M
authors.lastname: Divoka
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Pikalova
authors.forename: Karel
authors.initials: K
authors.lastname: Indrak
authors.forename: Katerina
authors.initials: K
authors.lastname: Langova
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D055815:Young Adult
chemical_list: D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan